Loading...
Prenetics Global Limited
PRENW•NASDAQ
Healthcare
Medical - Diagnostics & Research
$0.02
$-0.00(-1.58%)

Over the last four quarters, Prenetics Global Limited achieved steady financial progress, growing revenue from $5.43M in Q4 2023 to $7.78M in Q3 2024. Gross profit stayed firm with margins at 51% in Q3 2024 versus 49% in Q4 2023. Operating income totaled -$11.81M in Q3 2024, maintaining a -152% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$12.03M. Net income rose to -$10.67M, with EPS at -$0.84. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan